NybergSTBattyGDPenttiJ, et al. Obesity and loss of disease-free years owing to major non-communicable diseases: A multicohort study. Lancet Public Health2018;
3: e490–e497.
3.
WilliamsRAlexanderGArmstrongI, et al.
Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: Fourth report of the Lancet Standing Commission on Liver Disease in the UK. Lancet2018;
391: 1097–1107.
4.
Le RouxCWHartvigVNHaaseCL, et al. Obesity, cardiovascular risk and healthcare resource utilization in the UK. Eur J Prev Cardiol2020. Epub ahead of print, DOI: 10.1177/2047487320925639.
StefanNBirkenfeldALSchulzeMB, et al. Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol. Epub ahead of print 23 April 2020. DOI: 10.1038/s41574-020-0364-6.
7.
ParkJBKimDHLeeH, et al. Obesity and metabolic health status are determinants for the clinical expression of hypertrophic cardiomyopathy. Eur J Prev Cardiol. Epub ahead of print 1 December 2019. DOI: 10.1177/2047487319889714
8.
TongXWangXWangD, et al.
Prevalence and ethnic pattern of overweight and obesity among middle-aged and elderly adults in China. Eur J Prev Cardiol2019;
26: 1785–1789.
9.
KotsevaKDe BackerGDe BacquerD, et al.; EUROASPIRE Investigators.
Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol2019;
26: 824–835.
10.
SahaSGerdthamUGJohanssonP.Economic evaluation of lifestyle interventions for preventing diabetes and cardiovascular diseases. Int J Environ Res Public Health2010;
7: 3150–3195.
